Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) EBITDA (2019 - 2025)

Historic EBITDA for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to -$81.0 million.

  • Kymera Therapeutics' EBITDA fell 3848.3% to -$81.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$295.6 million, marking a year-over-year decrease of 8121.69%. This contributed to the annual value of -$224.8 million for FY2024, which is 5767.61% down from last year.
  • Per Kymera Therapeutics' latest filing, its EBITDA stood at -$81.0 million for Q3 2025, which was down 3848.3% from -$76.3 million recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' EBITDA registered a high of -$12.5 million during Q4 2023, and its lowest value of -$81.0 million during Q3 2025.
  • Moreover, its 5-year median value for EBITDA was -$41.0 million (2022), whereas its average is -$44.7 million.
  • As far as peak fluctuations go, Kymera Therapeutics' EBITDA skyrocketed by 6321.64% in 2023, and later plummeted by 49477.15% in 2024.
  • Over the past 5 years, Kymera Therapeutics' EBITDA (Quarter) stood at -$34.4 million in 2021, then increased by 1.49% to -$33.9 million in 2022, then skyrocketed by 63.22% to -$12.5 million in 2023, then plummeted by 494.77% to -$74.2 million in 2024, then dropped by 9.15% to -$81.0 million in 2025.
  • Its last three reported values are -$81.0 million in Q3 2025, -$76.3 million for Q2 2025, and -$64.2 million during Q1 2025.